Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENXBIO Inc. Director's Dealing 2018

May 30, 2018

32827_dirs_2018-05-30_790ea376-da51-4621-a5d3-c1382445f06b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2018-05-25

Reporting Person: Tasse Daniel (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-05-25 Stock Option (Right to Buy) $49.45 A 12500.00 Acquired 2028-05-25 Common Stock (12500.00) Direct

Footnotes

F1: The option will vest in 12 equal monthly installments following May 25, 2018.